| Psoriasis vulgaris
Tazorac vs Zoryve Foam
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Tazorac vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Tazorac based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Tazorac, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tazorac
Zoryve
At A Glance
Topical
Daily
Retinoid
Topical
Once daily
PDE4 inhibitor
Indications
- Psoriasis vulgaris
- Acne Vulgaris
- Seborrheic dermatitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Seborrheic dermatitis, Psoriasis vulgaris Apply a thin layer once daily to affected areas of body and/or scalp when not wet; rub in completely; for topical use only, not for ophthalmic, oral, or intravaginal use.
Contraindications
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Most common (>=1%) - Seborrheic dermatitis nasopharyngitis, nausea, headache
Most common (>=1%) - Psoriasis vulgaris headache, diarrhea, nausea, nasopharyngitis
Pharmacology
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
PDE4 inhibitor; roflumilast and its active N-oxide metabolite inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP; the specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Tazorac.
Zoryve
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Tazorac.
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
No coverage data available for Tazorac.
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tazorac.
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TazoracView full Tazorac profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.